Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986120 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A: BMS-986120 | ACTIVE_COMPARATOR | BMS-986120 on specified days |
| Treatment B: Aspirin and Clopidogrel | ACTIVE_COMPARATOR | Aspirin and Clopidogrel on specified days |
| Name | Type | Description |
|---|---|---|
| BMS-986120 | DRUG | - |
| Aspirin | DRUG | - |
| Clopidogrel | DRUG | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs and clinical laboratory determinations * Body...
Top 3 of 12 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 5 | PHASE3 | REGN7508, REGN9933 |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE2 | Thrombate III |
| Johnson & Johnson | JNJ | 1 | - | Rivaroxaban |
BMS-986120 is an investigational small molecule being studied for thrombosis, the formation of blood clots inside blood vessels. It is in Phase 1 clinical development for this cardiovascular indication. It has not been approved for any use, and its only recorded human study has been completed.
BMS-986120 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company sponsored the Phase 1 thrombosis chamber study of the compound conducted in the United Kingdom.
BMS-986120 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The program remains investigational, and BMS-986120 has not been approved by the FDA or any other regulatory authority for commercial use.
BMS-986120 has been evaluated in one completed Phase 1 study, NCT02439190, titled CV004-007 Thrombosis Chamber Study. It enrolled 42 participants aged 18 years and older in the United Kingdom, used an active-controlled randomized design, and included healthy volunteers.
BMS-986120 is a small molecule developed for thrombosis. It was studied in a Phase 1 thrombosis chamber model that assessed clot formation in healthy volunteers under active-controlled, randomized conditions, with 42 participants enrolled in the completed trial.